These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 19826051)
1. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051 [TBL] [Abstract][Full Text] [Related]
2. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433 [TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Kohga K; Takehara T; Tatsumi T; Ishida H; Miyagi T; Hosui A; Hayashi N Hepatology; 2010 Apr; 51(4):1264-73. PubMed ID: 20099300 [TBL] [Abstract][Full Text] [Related]
4. Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. Arai J; Goto K; Stephanou A; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Morimoto S; Kaise Y; Lim LA; Yoshida H; Kato N J Gastroenterol Hepatol; 2018 May; 33(5):1075-1081. PubMed ID: 29055152 [TBL] [Abstract][Full Text] [Related]
5. Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression. Twito T; Chen Z; Khatri I; Wong K; Spaner D; Gorczynski R Leuk Res; 2013 Jul; 37(7):816-21. PubMed ID: 23643150 [TBL] [Abstract][Full Text] [Related]
6. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cheung PF; Yip CW; Wong NC; Fong DY; Ng LW; Wan AM; Wong CK; Cheung TT; Ng IO; Poon RT; Fan ST; Cheung ST Cancer Immunol Res; 2014 Dec; 2(12):1209-19. PubMed ID: 25315249 [TBL] [Abstract][Full Text] [Related]
7. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004 [TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis. Ou ZL; Luo Z; Wei W; Liang S; Gao TL; Lu YB RNA Biol; 2019 Nov; 16(11):1592-1603. PubMed ID: 31402756 [TBL] [Abstract][Full Text] [Related]
9. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140 [TBL] [Abstract][Full Text] [Related]
10. Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10. Prox J; Willenbrock M; Weber S; Lehmann T; Schmidt-Arras D; Schwanbeck R; Saftig P; Schwake M Cell Mol Life Sci; 2012 Sep; 69(17):2919-32. PubMed ID: 22446748 [TBL] [Abstract][Full Text] [Related]
11. Tumor-associated MICA is shed by ADAM proteases. Waldhauer I; Goehlsdorf D; Gieseke F; Weinschenk T; Wittenbrink M; Ludwig A; Stevanovic S; Rammensee HG; Steinle A Cancer Res; 2008 Aug; 68(15):6368-76. PubMed ID: 18676862 [TBL] [Abstract][Full Text] [Related]
12. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells. Yuan S; Lei S; Wu S Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592 [TBL] [Abstract][Full Text] [Related]
13. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Jinushi M; Takehara T; Tatsumi T; Kanto T; Groh V; Spies T; Kimura R; Miyagi T; Mochizuki K; Sasaki Y; Hayashi N Int J Cancer; 2003 Apr; 104(3):354-61. PubMed ID: 12569559 [TBL] [Abstract][Full Text] [Related]
14. T-cell immunoglobulin and mucin domain 2 (TIM-2) is a target of ADAM10-mediated ectodomain shedding. Dewitz C; Möller-Hackbarth K; Schweigert O; Reiss K; Chalaris A; Scheller J; Rose-John S FEBS J; 2014 Jan; 281(1):157-74. PubMed ID: 24164679 [TBL] [Abstract][Full Text] [Related]
15. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo. Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394 [TBL] [Abstract][Full Text] [Related]
16. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. Liu G; Atteridge CL; Wang X; Lundgren AD; Wu JD J Immunol; 2010 Apr; 184(7):3346-50. PubMed ID: 20208009 [TBL] [Abstract][Full Text] [Related]
17. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536 [TBL] [Abstract][Full Text] [Related]
18. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Arai J; Goto K; Otoyama Y; Nakajima Y; Sugiura I; Kajiwara A; Tojo M; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Nozawa H; Nakagawa R; Muroyama R; Kato N; Yoshida H Cancer Immunol Immunother; 2021 Jan; 70(1):203-213. PubMed ID: 32683508 [TBL] [Abstract][Full Text] [Related]
19. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. Taylor DR; Parkin ET; Cocklin SL; Ault JR; Ashcroft AE; Turner AJ; Hooper NM J Biol Chem; 2009 Aug; 284(34):22590-600. PubMed ID: 19564338 [TBL] [Abstract][Full Text] [Related]